News
News
Local News
Crime & Public Safety
Your Tax Dollars At Work
Politics
Massachusetts
Nation
World
Business
Health
Weather
Columnists
Traffic
Sports
Sports
Red Sox
Patriots
Celtics
Bruins
College
High School
More Sports
Scores & Stats
Entertainment
Entertainment
Celebrity News
Arts & Culture
Movies
Television
Music
Fun & Games
Horoscope
Lottery
Comics
Puzzles
Lifestyle
Lifestyle
Food & Beverage
Travel
Style & Fashion
Obituaries
Obituaries
Local Obituaries
Submit an Obituary
Opinion
Opinion
Editorials
Op-Ed
Letters
Submit a Letter
Radio
Weather
E-Edition
Subscribe
Sign Up For Newsletters
News
News
Local News
Crime & Public Safety
Your Tax Dollars At Work
Politics
Massachusetts
Nation
World
Business
Health
Weather
Columnists
Traffic
Sports
Sports
Red Sox
Patriots
Celtics
Bruins
College
High School
More Sports
Scores & Stats
Entertainment
Entertainment
Celebrity News
Arts & Culture
Movies
Television
Music
Fun & Games
Horoscope
Lottery
Comics
Puzzles
Lifestyle
Lifestyle
Food & Beverage
Travel
Style & Fashion
Obituaries
Obituaries
Local Obituaries
Submit an Obituary
Opinion
Opinion
Editorials
Op-Ed
Letters
Submit a Letter
Radio
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Can-Fite BioPharma Ltd.
< Previous
1
2
3
Next >
Can-Fite Announces Exercise of Warrants for Approximately $5.0 Million in Gross Proceeds
August 08, 2024
From
Can-Fite BioPharma Ltd.
Via
GlobeNewswire
Can-Fite Provides Namodenoson Patent Update
July 29, 2024
From
Can-Fite BioPharma Ltd.
Via
GlobeNewswire
Join Can-Fite’s Exclusive Live Investor Webinar and Q&A Session on August 8
July 17, 2024
From
Can-Fite BioPharma Ltd.
Via
GlobeNewswire
Can-Fite Applies for FDA Orphan Drug Designation for Namodenoson in the Treatment of Pancreatic Cancer
July 11, 2024
From
Can-Fite BioPharma Ltd.
Via
GlobeNewswire
Improvement in Patient with Decompensated Liver Cirrhosis Upon Treatment with Namodenoson
July 01, 2024
From
Can-Fite BioPharma Ltd.
Via
GlobeNewswire
Positive Results from Osteoarthritis Clinical Study in Dogs Reported by Can-Fite’s Partner Vetbiolix
June 28, 2024
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Tickers
CANF
Can-Fite: Breakthrough Findings Demonstrate Namodenoson Anti-cancer and Protective Effect Mechanism in the Liver
June 24, 2024
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Tickers
CANF
Can-Fite Received IRB Approval for the Treatment of Pancreatic Cancer with Namodenoson in a Phase IIa Study
June 10, 2024
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Tickers
CANF
Can-Fite Updates on its Advanced Liver Cancer Pivotal Phase 3 Study
June 05, 2024
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Tickers
CANF
Independent Scientists Published a Review Article Demonstrating That Can-Fite Drugs Have Therapeutic Effects on Heart Diseases
May 29, 2024
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Tickers
CANF
Can-Fite to Participate in Partnering Meetings at Bio International Convention 2024
May 27, 2024
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Tickers
CANF
Join Can-Fite’s Exclusive Live Investor Webinar and Q&A Session on June 6
May 23, 2024
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Tickers
CANF
Can-Fite: 75 Oncologists and Coordinators from Europe US and Israel Participated in a Conference Aimed at Accelerating Patient Enrolment for the Pivotal Phase 3 Advanced Liver Cancer Study
May 13, 2024
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Tickers
CANF
Can-Fite: FDA Grants IND Clearance for Namodenoson to Treat MASH Patients in a Phase IIb Study
May 09, 2024
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Tickers
CANF
Can-Fite Received Notice of Allowance from the European Patent Office for the Treatment of Erectile Dysfunction with CF602
May 06, 2024
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Tickers
CANF
Long-term Complete Response to Can-Fite's Namodenoson in Patient with Advanced Liver Cancer: Article Published in a Leading Scientific Journal
April 25, 2024
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Tickers
CANF
Can-Fite: Scientific Article Published by KOL Presents Namodenoson as a Promising Drug Candidate to Treat Advanced Liver Cancer and MASH
April 15, 2024
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Tickers
CANF
Can-Fite: Submits FDA with an IND Application to Conduct Phase IIb Clinical Trial of Namodenoson in MASH Patients
April 03, 2024
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Tickers
CANF
Can-Fite Reports 2023 Financial Results and Clinical Update
March 28, 2024
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Tickers
CANF
Namodenoson Treatment for Pancreatic and Liver Cancer: Data will be Discussed in Out-licensing and Distribution Partnering Meetings at Bio Europe Conference
March 11, 2024
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Tickers
CANF
Can-Fite Broadens its Strong Intellectual Property (IP) for NASH: Received Patent Allowance in Canada
February 28, 2024
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Tickers
CANF
Can-Fite Expands the Out-Licensing Deal with Ewopharma to Include the Pancreatic Cancer Indication
January 30, 2024
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Tickers
CANF
Can-Fite: Top Scientific Journal Published Positive Data from the COMFORT-1 Phase III Psoriasis Study
January 29, 2024
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Tickers
CANF
The Anti-Obesity Effect of Can-Fite’s Namodenoson: Molecular Mechanism of Action in Pre-clinical and Human Studies
December 20, 2023
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Tickers
CANF
Can-Fite Received FDA Positive Response to Psoriasis Pediatric Plan
December 18, 2023
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Tickers
CANF
Can-Fite’s Namodenoson for the Treatment of Pancreatic Cancer Patients: Progress in Clinical Development
December 04, 2023
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Tickers
CANF
Can-Fite Reports Third Quarter 2023 Financial Results and Clinical Update
November 30, 2023
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Tickers
CANF
Can-Fite Announces Exercise of Warrants for Approximately $3.0 Million in Gross Proceeds
November 21, 2023
From
Can-Fite BioPharma Ltd.
Via
GlobeNewswire
Can-Fite: Complete Response and 6.9 Years Overall Survival in a Patient with Advanced Liver Cancer Treated with Namodenoson
November 21, 2023
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Tickers
CANF
Can-Fite Issues Business Update: All Clinical Programs and Business Development Activities Remain Solidly on Track
November 01, 2023
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Tickers
CANF
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
Close